Vinblastine and antihelmintic mebendazole potentiate temozolomide in resistant gliomas. (2018)

Peer-Reviewed Study · Franciele Cristina Kipper; Andrew Oliveira Silva; André Luis Marc et al. · April 2018

Franciele Cristina Kipper et al., 2018-04: Brazilian study using patient-derived glioma cultures and TCGA data to show that adding vinblastine and mebendazole to temozolomide reduces cell numbers more than temozolomide alone in TMZ-tolerant gliomas.

Combination treatment of vinblastine (VBL) plus mebendazole (MBZ) with TMZ was more effective in reducing cell number in most cultures when compared to TMZ alone, especially in cells with low expression levels of FGFR3 and AKT2.

Franciele Cristina Kipper et al., 2018-04: Brazilian study using patient-derived glioma cultures and TCGA data to show that adding vinblastine and mebendazole to temozolomide reduces cell numbers more than temozolomide alone in TMZ-tolerant gliomas. Study type: patient-derived glioma cell cultures plus TCGA bioinformatics. N: cultures from patients, number not stated in the abstract; no animals. Country: Brazil (Federal University of Rio Grande do Sul, Porto Alegre). Dose: not stated in the abstract text captured. Funder: FAPERGS (PPSUS 1210-2551/13-1; PRONEX 16/2551). Declared conflicts: no COI statement in the record. Comparator: temozolomide alone, and the doublets. PARTLY AND WITH A CORRECTION: this is an in vitro study, so it does not support a statement that mebendazole-plus-temozolomide has been tested in animal glioma models. Study type: lab.